FDA approves Nucala as add-on therapy for COPD with high eosinophils, offering new hope by reducing flare-ups in patients ...

Dunn, PharmD, MBA: [Summarize] the nonmedication strategies that we can use to optimize the management of COPD [chronic obstructive ... of course, treatment for tobacco [addiction] and tobacco ...

Arguably the most buzzed about advancement in the COPD treatment landscape is the emergence ... that are able “to target very specific immune pathways,” Han explains. Essentially, these ...

A robust treatment plan for COPD includes a combination of prescription medication, pulmonary therapies, and healthy lifestyle changes to help relieve symptoms and slow disease progression.

It can affect how you exercise, work, and do other daily activities. The goals of COPD treatment are to reduce symptoms and symptom flare-ups. "This can be done through a combination of lifestyle ...

The FDA granted approval to mepolizumab for treating adults with inadequately controlled COPD and an eosinophilic phenotype, ...

Not only are the neutrophils overstimulated, their pathways of activation and ... become more aware of their benefits in COPD. Corticosteroid treatment may be detrimental to the effectiveness ...

In 2019, COPD was responsible for ... all designed to act on specific molecular pathways and tailored to selected patient populations. Beyond drug treatments, several non-pharmacological ...

Most COPD treatments come as inhalers ... Tamping down the IL-13 pathway could also help regulate mucus production in the lungs. A pair of late-stage clinical trials showed Dupixent was effective ...

Standard treatment includes drugs and drug ... designed to block IL-13 and IL-4, two signaling pathways that drive inflammation. In COPD, the drug is intended to specifically address type 2 ...

A new COPD drug, developed by Verona Pharma, was approved by the FDA Wednesday. The drug, ensifentrine, is the first new type of maintenance treatment for COPD in over a decade. In clinical trials ...